H.F. Günthard

Discipline

Economies et finances (10) Anthropologie biologique (5) Sociologie (4) Démographie (1)

Type de document

Articles (111)

Co-auteur

Date

Source

Mot-clé

cohorte (74) Human beings (70) Treatment (64) Swiss (64) thérapie (56) Therapeutics (56) Patients (55) Patients (55) virus (44) Infection (40) Immunodeficiency (39) infection (38) Population (37) temps (durée) (36) risque (36) Time (36) Risk (36) Transmission (35) analyse (34) Ci (Chinese poetry) (34) Population (34) Analysis (34) Methods (31) Methods (31) Models (31) association (29) Social groups (29) Use (29) Confidence (28) art (27)

Documents écrit par H.F. Günthard (111) | parle de H.F. Günthard (0)

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
P. Thoueille et al.
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trial.
A. Marinosci et al. (15 avr. 2024)
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
L. Begré et al.
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
P. Thoueille et al.
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland.
M. Zeeb et al. (11 nov. 2023)
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).
A. Griessbach et al.
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
J.M. Schwenke et al. (15 sept. 2023)
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
B. Surial et al. (11 sept. 2023)
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
B. Jaha et al. (5 sept. 2023)
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.
E.F. Avery et al. (8 juin 2023)
Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.
I.C. Schoepf et al.
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
A. Griessbach et al.
Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.
M. Hepprich et al.
Unsupervised machine learning predicts future sexual behaviour and sexually transmitted infections among HIV-positive men who have sex with men.
S. Andresen et al.
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.
B. Speich et al. (24 août 2022)
A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits.
S. Nadeau et al. (3 août 2022)
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics.
K. Kusejko et al. (1 août 2022)
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
P. Thoueille et al. (29 juil. 2022)
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients.
K. Kusejko et al. (28 juil. 2022)
Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.
A.G. Bick et al. (8 juil. 2022)
An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters.
K. Kusejko et al. (10 avr. 2022)
Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.
D. Seifert et al. (16 févr. 2022)
Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.
A.G. Bick et al. (12 janv. 2022)
Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load.
L. Zhao et al. (2022)
Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection.
L. Begré et al. (2022)

next